TIGIT/CD226 Axis Regulates Anti-Tumor Immunity
Tumors escape immune surveillance by inducing various immunosuppressive pathways, including the activation of inhibitory receptors on tumor-infiltrating T cells. While monoclonal antibodies (mAbs) blocking programmed cell death 1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T lymphocyte-...
Saved in:
Main Authors: | Jinah Yeo (Author), Minkyung Ko (Author), Dong-Hee Lee (Author), Yoon Park (Author), Hyung-seung Jin (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Generating Anti-TIGIT and CD155 Monoclonal Antibodies for Tumor Immunotherapy
by: Yu-Hang Duan, et al.
Published: (2022) -
Structural and functional characterization of a monoclonal antibody blocking TIGIT
by: Bo-Seong Jeong, et al.
Published: (2022) -
Targeting TIGIT for cancer immunotherapy: recent advances and future directions
by: Peng Zhang, et al.
Published: (2024) -
CD226 gene polymorphisms are associated with non-small-cell lung cancer in the Chinese Han population
by: Qiu ZX, et al.
Published: (2015) -
Biophysical characterization of PVR family interactions and therapeutic antibody recognition to TIGIT
by: SJ J. Diong, et al.
Published: (2023)